StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bernstein SocGen Reiterates Underperform Rating on Summit Therapeutics plc (SMMT)
June 1, 2026 8:23 AM
Bernstein SocGen Group analyst Jeffrey Walch reiterated an Underperform rating and $7.70 price target on Summit Therapeutics plc (NASDAQ: SMMT).The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
